Levorol

Levomepromazine, the active ingredient in Levorol, is a phenothiazine presented as an oral tablet for oral use. It is employed in the management of schizophrenia, severe agitation, nausea and vomiting, and as a sedative in palliative‑care settings for adult patients.

GNH USA supplies Levorol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levorol (levomepromazine) acts on dopaminergic pathways and is indicated for several psychiatric and supportive‑care conditions.

- Schizophrenia: helps control psychotic symptoms such as delusions and hallucinations. - Severe agitation: calms acute behavioral disturbances when rapid sedation is required. - Nausea and vomiting: reduces emesis associated with chemotherapy, postoperative states, or other causes. - Palliative care: provides symptom control for pain, anxiety, and distress in terminal illness.

Levomepromazine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: excessive sleepiness or fatigue. - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: drop in blood pressure upon standing. - Blurred vision: temporary visual disturbances. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing heart disease. - Agranulocytosis: dangerous drop in white blood cells. - Seizures: occurrence of convulsive episodes. - Tardive dyskinesia: persistent involuntary movements after prolonged use.

When prescribing levomepromazine, clinicians should observe several safety measures.

- Blood pressure monitoring: check for orthostatic hypotension, especially after dose changes. - Cardiac assessment: evaluate for QT prolongation or existing arrhythmias. - Extrapyramidal vigilance: watch for signs of movement disorders. - Elderly caution: start low and increase slowly to reduce sedation and falls. - Discontinuation: avoid abrupt cessation to prevent withdrawal phenomena. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levomepromazine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - CNS depressants: may intensify sedation and respiratory depression. - Anticholinergic agents: increase risk of severe anticholinergic toxicity. - Antihypertensives: additive hypotensive effect. - Other dopamine antagonists: enhance extrapyramidal symptoms. - MAO inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors/inducers: may change levomepromazine plasma levels. - Alcohol: potentiates central nervous system depression. - Antihistamines: increase sedation. - SSRIs: monitor for serotonin syndrome. - Antiepileptics: may affect seizure threshold.